HER-2-positive gastric cancer accompanied by liver metastasis: a case report of a rare complete response and literature review
  
View Full Text  View/Add Comment  Download reader
DOI:
KeyWord:HER-2  gastric cancer  liver metastasis  CR  chemotherapy
                    
AuthorInstitution
Hongmei Yong Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Yeping Du Department of Intensive Care Unit, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Wei Wang Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Huichang Shi Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Ronghui Cheng Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Xuan Jiang Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Xueyi Zhou Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and the Second Huai’an People’s Hospital, Huai’an, Jiangsu 223002, China.
Hits: 116
Download times: 134
Abstract:
      The prognosis of advanced gastric cancer is poor, and the prognosis of late-stage gastric cancer with expression of human epidermal growth factor receptor 2 (HER-2) is worse. Personalized therapy is based on the specific situation of each patient to determine the best treatment plan. We diagnosed a 36-year-old patient with a HER-2-producing adenocarcinoma of the gastric cardia accompanied by liver metastasis. Sixteen cycles of chemotherapy were consecutively administered to the patient, starting with a three-drug combination, followed by a two-drug combination, and finally a single drug as a chemotherapy regimen. During these treatments, the molecular targeted drug trastuzumab was continuously administered. In the end, the patient experienced a complete response (CR). In clinical practice, advanced gastric cancer is not well controlled in certain patients, due to inadequate first-line chemotherapy and its side-effects. If a patient enjoys a strong performance status (PS), we emphasize the importance of molecular-targeted drugs combined with prolonged administration of chemotherapy.
Close